Literature DB >> 2807776

Radical nephrectomy through total median laparotomy.

L Pajor1, D Frang, V Szabó, D Répássy.   

Abstract

Twenty-two carcinoma patients aged less than 65 years were subjected to radical nephrectomy through total median laparotomy. This type of approach provides excellent access to both essential operation phases: vessel management and lymphadenectomy. Postoperative abdominal complications and hernia have not been encountered.

Entities:  

Mesh:

Year:  1989        PMID: 2807776     DOI: 10.1007/bf02559734

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  7 in total

1.  Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases.

Authors:  D G Skinner; R B Colvin; C D Vermillion; R C Pfister; W F Leadbetter
Journal:  Cancer       Date:  1971-11       Impact factor: 6.860

2.  The role of lymphadenectomy in the management of renal cell carcinoma.

Authors:  P C Peters; G L Brown
Journal:  Urol Clin North Am       Date:  1980-10       Impact factor: 2.241

3.  Transitional cell carcinoma in ureteral stump after radical nephrectomy for renal cell carcinoma.

Authors:  L F Grey; R F Sorial; H J Levin
Journal:  Urology       Date:  1987-02       Impact factor: 2.649

4.  Surgical approach to inferior vena caval extension of renal carcinoma.

Authors:  M K O'Donohoe; F Flanagan; J M Fitzpatrick; J M Smith
Journal:  Br J Urol       Date:  1987-12

5.  [Primary metastasized hypernephroma: therapy and follow-up].

Authors:  V G Hienert; D Latal; J Kühböck; S Rummelhardt
Journal:  Z Urol Nephrol       Date:  1987-12

6.  Surgical management of renal cell carcinoma with vena cava tumor thrombus.

Authors:  L Giuliani; C Giberti; G Martorana; S Rovida
Journal:  Eur Urol       Date:  1986       Impact factor: 20.096

7.  Renal cell carcinoma: survival and prognostic factors.

Authors:  M Golimbu; P Joshi; A Sperber; A Tessler; S Al-Askari; P Morales
Journal:  Urology       Date:  1986-04       Impact factor: 2.649

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.